IL-1Ra (recombinant human IL-1 receptor antagonist) in the treatment of rheumatoid arthritis: The efficacy;IL-1Ra (antagonista umano ricombinante del recettore dell'IL-1) nel trattamento dell'artrite reumatoide: L'efficacia

Reumatismo

Volumn 56, Issue 1 SUPPL. 1, 2004, Pages 62-73

  Fiocco, Ugo ^a   Vezzu M ^a   Cozzi, L ^a   Todesco, S ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Biologic agents; Efficacy; Recombinant human IL 1 receptor antagonist; Rheumatoid arthritis; Therapy

Indexed keywords

INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; CANCER; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DEMYELINATION; DRUG CHOICE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; LYMPHOMA; MONOTHERAPY; PATHOPHYSIOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; TUBERCULOSIS;

ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; SIALOGLYCOPROTEINS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2342510238     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Balavoine J, de Rochemonteix B, Cruchaud A, Dayer J-M. Collagenase and PGE2-stimulating activity (interleukin-1-like) and inhibitor in urine from a patient with monocytic leukaemia Prog Leukocyte Biol 1985; 2: 429-36.
2. Seckinger P, Lowenthal JW, Williamson K, Dayer J-M, Mac Donald HR. A urine inhibitor of interleukin 1 activity that blocks ligand binding. J Immunol 1987; 139: 1546.
3. Seckinger P, Klein-Nulend J, Alander C, Dayer J-M, Mac Donald HR. Natural and recombinant human interleukin-1 receptor antagonist blocks the effects of IL-1 on bone reasorption and prostaglandin production. J Immunol 1990; 145: 4181-4.
4. Hannum C, Wilcox CJ, Arend WP, Joslin FG, Dripps DJ, Heimdal PL, et al. Interleukin 1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990; 343: 336-40.
5. Arend WP. Interleukin 1 receptor antagonist: a new member of the interleukin 1 family. J Cin Invest 1991; 88: 1445-51.
6. Eisenberg SP, Evans RJ, Arend WP, Verderber E, Brewer MT, Hannum CH, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990; 343: 341.
7. Arend WP, Dayer J-M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990; 33: 305-15.
8. Lebsak ME, Paul CC, Bloedow DC, Burch FX, Sack MA, Chase W Subcutaneous IL-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1991; 34 Suppl 9: S45.
9. Firerstein GS, Boyle DL, Yu C, Paine MM, Whisenand TD, Zvaifler NJ et al. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 1994; 37: 644-52.
10. Arend WP, Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995; 38: 151-60.
11. Dinarello CA. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 2000; 343: 728-30.
12. Dayer JM, Feige U, Edwards CK 3rd, Burger D. Anti-interleukin-1 therapy in rheumatic diseases. Curr Opin Rheumatol 2001; 13: 170-6.
13. Joosten LA, Ootes L, den Broeder A. Variations in IL-17, IL-1, and TNF expression patterns in synovial biopsies of active RA patients. Arthritis Rheum 2000; 43: S83.
14. van den Berg W.B, Joosten LA, Kollias G, van de Loo FA. Role of tumor necrosis factor alpha in experimental arthritis: separate activity of interleukin-1 beta in chronicity and cartilage destruction. Ann Rheum Dis 1999; 58 (Suppl 1): 140-8
15. van den Berg WB, Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis: evidence of a dominant role for interleukin-1. Ballière's Clin Rheum 1999; 13: 577-97.
16. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1092-101.
17. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196-204.
18. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 1993; 36: 729-740.
19. Bresnihan B, Chan WW, Wolley JM. Increases in productivity after six and twelve months of anakinra treatment in patients with rheumatoid arthritis. Arthritis Rheum 2001; 44: S77.
20. Emery P, Woolley JM, Chan WW. Improvement in health- related quality of life from anakinra therapy in patients with rheumatoid arthritis not using DMARDs. Ann Rheum Dis 2001; 44: S77.
21. Nuki G, Bresnihan B, Bear BM, McCabe D. Long term safety and maintenance of clinical improvement following treatment with anakinra (Recombinant human IL-1 receptor antagonist) in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46: 2838-46.
22. Cunnane G, Madigan A, Murphy E, FitzGerald O, Bresnihan B. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumtology 2001; 40: 62-9.
23. Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 2000; 43: 1001-09.
24. Genant HK, Jiang Y, Peterfy C, Lu Y, Redei J, Countryman PJ. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum 1998; 41: 1583-90.
25. R) inhibits the progression of radiographically measured joint destruction in rheumatoid arthritis. Arthritis Rheum 2002; XXS443.
26. Bresnihan B. Effects of anakinra on clinical and radiological outcomes in rheumatoid arthritis. Ann Rheum Dis 2002; 61: Suppl II: ii74-ii77.
27. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with Anakinra, a recombinant human IL-1 receptor antagonist, in combination with methotrexate. Results of twenty-four-week, multicenter, randomised, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 614-24.
28. Cohen S, Moreland LW, Cush J. et al. Anakinra (Recombinant IL-1 receptor antagonist): a large, placebo controlled efficacy trial of anakinra in patients with erosive rheumatoid arthritis disease. Arthritis Rheum 2001, 44: SXX.
29. Fleischmann RM, Schechtman J, Bennett R, Malcolm HL, Burmester GR, Tesser J, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003; 48: 927-34.
30. Il 1-Ra as a new biological approach for the treatment of rheumatoid arthritis. Ed.: Cutolo M, Bresnihan B, Dayer J-M. Clin Exp Rheum 20: 5, Supp. 27, 2002.
31. Bresnihan B. The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Biodrugs 2001; 15: 87-97.
32. Dayer J-M, Bresnihan B. Targeting Interleukin-1 in the treatment of Rheumatoid Arthritis. Editorial. Arthritis Rheum 2002; 46: 574-8.